 | Bayer HealthCare’s R&D focuses on identifying and developing new active substances for treating diseases with high unmet medical need. The initiative seeks to identify and develop novel small-molecule leads, particularly
in the fields of oncology, cardiology, hematology and gynecological therapies. |
 | Eli Lilly has established a programme to provide academic investigators access to proprietary, disease-relevant phenotypic assays (PD2) and sophisticated in vitro target-based assays (TargetD2) for the screening of small molecules targeting
cancer, neurological disorders and metabolic diseases. |
 | ACE is a virtual research network pursuing projects of mutual interest to GSK and Singapore academic scientists and developing partnerships to accelerate translational research and progress our shared goal of making new medicines available
to the patients that need them.
Discovery Partnerships with Academia
|
 | The LIMR Chemical Genomics Center connects university and pharma scientists in a new way to validate ‘druggability’ of innovative cell-signaling targets through a new translational-research framework for public-private
partnering. Double-Blinded Drug Discovery® (DBD2). |
 | The Merck Investigator Studies Programme is designed to advance science and improve patient care by supporting, through the provision of drug/vaccine and/or total/partial funding, high-quality research that is initiated, designed, implemented
and sponsored by external investigators. |
 | Samsung GRO programme is open to leading universities around the world. Samsung, through its Samsung Advanced Institute of Technology, invites universities to submit innovative research proposals on an annual basis, in alignment with Samsung’s
many different research fields. |